← Back to Search

CI OBVAT for Convergence Insufficiency

N/A
Waitlist Available
Research Sponsored by New Jersey Institute of Technology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
diagnosis of symptomatic convergence insufficiency binocularly normal control
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

Convergence insufficiency (CI) is a prevalent binocular vision disorder with symptoms that include double/blurred vision, eyestrain, and headaches when engaged in reading or other near work. CI is present in 4% of the population where approximately 27% of CI patients do not improve even with validated therapy. The project will quantitatively study changes in convergence eye movements and neural substrates before and after validated therapy in CI patients. This knowledge can lead to improvements in currently validated therapy, reduction in therapy sessions, and reduced healthcare costs.

Eligible Conditions
  • Convergence Insufficiency

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disparity Vergence Response Amplitude

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: CI OBVATActive Control1 Intervention
Patients with Convergence Insufficiency in Active Vision Therapy
Group II: Controls OBVATActive Control1 Intervention
Control receive active therapy
Group III: Controls ShamPlacebo Group1 Intervention
Subjects with Normal Binocular Vision will receive a therapy that appears to be therapeutic but does not have any binocular coordination benefits.
Group IV: CI Sham therapyPlacebo Group1 Intervention
CI Sham therapy

Find a Location

Who is running the clinical trial?

New Jersey Institute of TechnologyLead Sponsor
8 Previous Clinical Trials
843 Total Patients Enrolled
4 Trials studying Convergence Insufficiency
564 Patients Enrolled for Convergence Insufficiency
National Eye Institute (NEI)NIH
548 Previous Clinical Trials
1,401,775 Total Patients Enrolled
6 Trials studying Convergence Insufficiency
1,143 Patients Enrolled for Convergence Insufficiency
Atam Dhawan, PhDStudy DirectorNew Jersey Institute of Technology
~9 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top